Widest range of medical cannabis products in the Australian market
NYSE | TSX: ACB
EDMONTON, AB, January 27, 2021 / CNW / – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company that defines the future of cannabinoids worldwide, announced today that it has entered into a strategic agreement closed with MedReleaf in Australia (“MedReleaf”). The companies have signed a five-year supply agreement that provides for MedReleaf to act as the exclusive supplier in Australia of the brands MedReleaf, CanniMed and Aurora by Aurora. Products covered by the agreement will be EUGMP certified and include dried flowers, oils and soft gels, as well as future products with new delivery mechanisms. The agreement does not require or involve any capital investment by Aurora.
MedReleaf Australia, in which Aurora has a 10% stake, is a fully licensed private company that has been in the Australian medical cannabis sector since 2016. MedReleaf and Aurora are currently supplying products to the Australian medical cannabis system. This agreement will accelerate the supply and expansion of the availability of high quality medical cannabis to patients. MedReleaf is one of the six founding members of the Medicinal Cannabis Industry Australia (MCIA) trade association.
“We are pleased to have established a long-term strategic relationship with MedReleaf to exclusively sell the Aurora, CanniMed and MedReleaf brands Australia, “said Miguel Martin, CEO of Aurora. “The MedReleaf team has in Australia To assist doctors, pharmacists and patients across the country with access to quality Aurora cannabis medicines. ”
Russell Harding, CEO of MedReleaf, added: “Australia The medical cannabis system is well designed, well regulated and one of the fastest growing in the world. Our strategic supply agreement with Aurora ensures that our patients have reliable access to cannabis medicines that are known worldwide for their quality and meet the strict requirements of Aurora Australia Management of therapeutic goods. In order to support the common goals of our companies in the Australian market, we will focus with care and discipline on expanding our patient and prescriber base. “
Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquarters in Edmonton, AlbertaAurora is a pioneer in global cannabis helping people improve their lives. The company’s portfolio of brands includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler and Reliva CBD. Aurora’s brands deliver innovative, high quality cannabis products to their customers and continue to lead the industry in medical, performance, wellness and leisure wherever they are introduced. For more information, please visit our website at www.auroramj.com.
Aurora common stock trades on the TSX and NYSE under the symbol “ACB” and is part of the S & P / TSX Composite Index.
This press release contains statements that contain certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are often identified by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential” “,” suggested “and other similar words or statements suggest that certain events or conditions” may “or” will “occur. Forward-looking statements in this press release include statements regarding the supply of cannabis products to MedReleaf Australia. These forward-looking statements are only predictions. Various assumptions have been made in order to reach conclusions or to predict the forward-looking statements contained in this press release. Forward-looking statements are based on the opinions, estimates and assumptions of the management in the light of the experience of the management and the perception of historical trends, current conditions and expected developments at the time the statements are made, such as current and future market conditions, the ability to maintain them. Cost is in line with current expectations, the ability to generate high margin income in the Canadian consumer market, current and future regulatory environments, and future permits and permits. Forward-looking statements are subject to a number of risks, uncertainties and other factors that management believes are relevant and appropriate in the given circumstances and that could cause actual events, results, levels of activity, performance, prospects, opportunities or successes to differ materially from them Projected in the forward-looking statements, including the risks associated with entering the U.S. market, the ability to realize the anticipated benefits related to the Reliva acquisition, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in law and the associated risks include regulations, product demand, changes in the price of required goods, competition, effects and reactions to the COVID-19 pandemic and other risks, uncertainties and factors that are covered under the heading “Risk Factors” in the annual informati Company’s onsheet is dated September 24, 2020 (the “AIF”) and filed with the Canadian Securities and Exchange Commission, which are available on the Company’s Issuer Profile on SEDAR at www.sedar.com and on the SEC’s website at www.sec.gov for use of the proceeds from the Change offer. The company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and that other factors could also affect results. Readers are cautioned to carefully consider the risks, uncertainties and assumptions in evaluating any forward-looking statements and are cautioned not to place undue reliance on such information. The company is under no obligation and expressly disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information, future events or for other reasons, unless this is expressly required by the applicable securities law.
SOURCE Aurora Cannabis Inc.
For more information: For the media: Michelle Lefler, VP, Communications & PR, [email protected];; For investors: ICR, Inc., Investor Relations, [email protected]